Small non-coding RNAs (sRNAs) act in conjunction with the RNA chaperone Hfq to regulate gene expression in bacteria. Because Hfq is required for virulence in several bacterial pathogens, the Hfq-sRNA system is an attractive target for antibiotic development. A reporter strain in which the expression of yellow fluorescent protein (YFP) is controlled by Hfq-sRNA was engineered to identify inhibitors of this system. A reporter that is targeted by Hfq in conjunction with the RybB sRNA was used in a genetic screen to identify inhibitors from a library of cyclic peptides produced in E. coli using SICLOPPS, an intein-based technology. One cyclic peptide identified in this screen, RI20, inhibited Hfq-mediated repression of gene expression in conjunction with both RybB and an unrelated sRNA, MicF. Gel mobility shift assays showed that RI20 inhibited binding of Hfq to RybB and MicF with similar K I values. These data suggest that RI20 inhibits Hfq activity by blocking interactions with sRNAs, and provide a paradigm for inhibiting virulence genes in Gram-negative pathogens.
Introduction
The spread of resistance to existing antibiotics represents a serious challenge to the public health sector. A recent CDC report estimated that >2 million people in the United States are infected by drug-resistant bacteria annually, causing over 20,000
fatalities (1) . The limited pool of potential antibiotics in the development pipeline creates an urgent need to identify new antibiotic targets (1, 2) . Targets that could be inhibited to prevent virulence, and that do not create a strong selective pressure to drive the spread of resistance, would be especially valuable. In principle, inhibitors of bacterial pathways required for virulence but not viability could be used to treat infections. Because selective pressure for resistance to such inhibitors would be lower under some growth conditions compared to the strong selection for resistance to lethal inhibitors, the spread of resistance might be slower and the clinical lifetime of the drugs might be longer (3, 4) .
One approach to targeting virulence is to inhibit regulatory pathways that control the expression of genes required for a pathogen to cause disease in a host during infection.
Hfq is a member of the Sm-like family of RNA binding proteins and acts as an RNA chaperone for small regulatory RNAs (sRNAs). Hfq binds with sRNAs and promotes base-pairing interactions between the sRNAs and their mRNA targets (16) (17) (18) .
sRNAs regulate expression of their target mRNAs in a variety of ways, often by inhibiting translation (19, 20) . Hfq-sRNA activity also promotes degradation of the mRNA targets by the RNA degradasome (21) . Because most sRNAs require Hfq for activity, inhibitors of Hfq are likely to disrupt a significant portion of sRNA-mediated transcriptional regulation.
To allow discovery of specific Hfq inhibitors that could be used to validate Hfq as a therapeutic target, a cell-based assay for inhibition of Hfq activity was developed and tested. The assay uses a fluorescent reporter placed under control of the RybB sRNA in conjunction with Hfq. Libraries of cyclic peptides were generated inside bacterial cells using SICLOPPS, an intein-based technology (22) . SICLOPPS allows the spontaneous circular ligation of peptide sequences. By randomizing codons in the SICLOPPS target sequence, libraries of cyclic peptides with large sequence diversity can be generated inside bacterial cells (23) . In this work, a SICLOPPS library with five randomized codons, encoding ~10 6 different cyclic peptides, was screened for potential inhibitors of Hfq-
RybB. A peptide was identified that inhibited repression of target gene expression by
Hfq-RybB. This peptide was also able to inhibit Hfq-dependent regulation by a second sRNA, MicF. In both cases, the peptide reduced the affinity of Hfq for the sRNA in vitro.
These results indicate that Hfq is a druggable target and facilitate identification of inhibitors of Hfq from libraries of potential pharmaceuticals.
Materials and Methods

Bacterial strains and growth conditions
Strains used in this study are described in Table 1 . All the reporter strains used for in vivo screening are derivatives of E. coli strain BW27786 (24) . Mutant alleles lacI q and hfq were moved into the appropriate strains using P1 transduction and the drugresistance markers were removed using FLP recombinase (25) . E. coli strains were grown in LB at 30 °C with aeration unless otherwise noted. 100 g/ml ampicillin, 30 g/ml kanamycin, 30 g/ml chloramphenicol, and 0.0002% arabinose were added where appropriate.
Plasmid construction
Plasmids used in this study are described in Table 1 and oligonucleotide sequences are listed in Table 2 . To make pompC'-yfp, the region of ompC that binds RybB was amplified by PCR from genomic DNA using primers ompCE and ompCB.
The yfp gene was amplified by PCR using primers egfpB and egfpSA. Both PCR products were digested with BspHI, ligated using T4 DNA ligase, and the resulting ompC'-yfp fusion was amplified by PCR using primers ompCE and egfpSA, digested with EcoRI and SalI, and ligated into pBAD18K cut with the same enzymes to make the pBOY plasmid. The tet control region was amplified by PCR from pAS08 using primers pAS081 and pAS081R, and digested with EcoRI and KpnI. The ompC'-yfp fusion was amplified from pBOY by PCR using primers ompCK and egfpSp, digested with KpnI and SpeI, and ligated to the tet control region fragment. The ligated product was amplified by PCR using primers pAS081 and egfpSp, digested with EcoRI and SpeI, and ligated into pSB4K5 cut with the same enzymes to produce pompC'-yfp.
For the construction of pompF'-yfp, the region of the ompF gene targeted by sRNAs was amplified from genomic DNA by PCR using primers ompF-Brev and ompF-110, digested with BspHI and KpnI, and ligated into pompC'-yfp cut with the same enzymes.
Hfq was amplified by PCR from genomic DNA using primers Hfqfwd_NcoI and Hfqrev_EcoRI, digested with NcoI and EcoRI, and ligated into pET28a cut with the same enzymes. The SGWX 5 SICLOPPS library was constructed as previously described (23) .
Screen for inhibitors of Hfq-RybB
E. coli strain SAE008 was transformed with the SICLOPPS plasmid library, and resulting colonies were scraped, grown overnight in LB with 30 g/ml chloramphenicol, 100 g/ml ampicillin, 30 g/ml kanamycin and 0.0002% arabinose at 30 °C, diluted 100-fold, and grown under the same conditions to OD600 0.2. Expression of RybB was induced by addition of IPTG to 1 mM for 1 h, followed by induction of ompC'-yfp by addition of anhydrous tetracycline (AHT) to 100 ng/ml for 3 h. Cells were sorted by fluorescence activated cell sorting (FACS) using a Cytopeia Influx (Becton Dickinson) cell sorter equipped with a 200 mW 488 nm laser and a 531/40 bandpass filter for Fluorescent reporter and control strains were grown in LB with the appropriate antibiotics and arabinose at 30 °C, diluted to OD 600 = 0.02, and grown under the same conditions to OD 600 = 0.2, expression of sRNA was induced by addition of IPTG to 1 mM for 1 h, and expression of the fluorescent reporter was induced by addition of AHT to 100 ng/ml for 3 h prior to observation and quantification by epifluorescence microscopy. All experiments were done in triplicate. To confirm expression of cyclic peptides, cells were harvested in volumes normalized to the OD 600 and lysed in SDS-PAGE loading buffer. Proteins were separated on 15% SDS-polyacrylamide gels, blotted to PVDF membranes, and the full-length SICLOPPS proteins were visualized by Western blotting using anti-CDB antibodies (New England BioLabs) with goat-anti-rabbit secondary antibody and ECF reagent (GE Healthcare). The full-length SICLOPPS protein contains a chitin-binding domain (CBD) that is removed upon cyclization.
Therefore the level of CBD is indicative of cyclic peptide expression levels. The relative amounts of proteins were determined using a Typhoon 9410 (GE Healthcare) and quantified using ImageQuant (Molecular Dynamics).
Assays with synthetic RI20 (ChinaPeptides Co., Ltd.) were performed in a similar manner, except arabinose was not included and RI20 was added to 500 M during growth.
Because RI20 was dissolved in DMSO, in control reactions cells were incubated with 1% DMSO instead of RI20.
For assays in 96-well plates, cultures were grown and induced with IPTG as described above, and 100 μl was transferred to microtiter trays. Trays were incubated at 37 °C for 45 min, AHT was added, and trays were incubated at 37 °C for 6 h. 
Northern blot analysis
Strain SAE195 was grown with or without addition of 0.0002% arabinose to OD 600 = 1.5 in the presence of IPTG and AHT, cells were harvested by centrifugation, and RNA was prepared using the hot phenol method (27 
Hfq purification
Untagged Hfq was purified from E. coli BL21 (DE3) transformed with pET28a_hfq, using Co 2+ -affinity chromatography as described (28), with modifications.
Cultures were grown to OD 600 = 0.4, expression was induced by addition of IPTG to 1 mM, and cultures were grown for 4 h. Cells were harvested by centrifugation, and the cell pellet was resuspended in 50 ml lysis buffer (50 mM Tris-HCl (pH 7.5), 500 mM NH 4 Cl, 20 mM imidazole, 5% w/v glycerol). Lysozyme was added to a final concentration of 1 mg/ml, the suspension incubated on ice for 30 min, and cells were lysed by sonication. 1 U DNase I and 1 g/ml RNase A were added, the lysate was incubated on ice for 1 h, and debris was removed by centrifugation. column volumes of buffer A1, and bound protein was eluted with a linear gradient from 0-2 M NaCl in buffer A1. Protein was dialysed against storage buffer (50 mM Tris-HCl (pH 7.5), 100 mM NH 4 Cl, 1 mM EDTA, 10% glycerol) and stored at -20 °C.
In vitro transcription of RybB and MicF RNA
Templates for in vitro transcription were PCR products amplified from pKMT5 plasmid using primers RybB_fwd and RybB_rev for rybB, or pMicF plasmid using 
Electrophoretic mobility shift assays
Binding assays were performed in 1X binding buffer ( 
Stress sensitivity assays
For hydrogen peroxide sensitivity assays, 3 ml LB top agar was inoculated with 30 μl saturated culture, plated on LB agar, and allowed to solidify. 10 μl 3% hydrogen peroxide was added to a 6 mm filter paper disk, and the disk was placed on the top agar.
After incubation overnight, the diameter of the zone of inhibition was measured.
Averages and standard deviations for >4 independent experiments were calculated.
For antibiotic sensitivity assays, broth microdilution assays were conducted as previously described (29) . The minimum inhibitory concentration (MIC) was determined from visual inspection, and the IC 50 was determined after measuring the OD 600 and on November 12, 2017 by guest http://aac.asm.org/ plotting the percent growth inhibition versus antibiotic concentration. Experiments were performed in triplicate.
Molecular docking
Molecular docking studies were performed using AutoDock Vina (The Scripps
Research Institute) with AutoDock Tools graphical user interface, and energy minimization was performed using the OpenBabel module. The E. coli Hfq crystal structure (PDB ID: 1HK9) was used to calculate protein receptor grid maps using the AutoGrid module, and RI20 was docked using the Lamarckian Genetic Algorithm. A combination of the highest dock scores and the lowest root mean square deviation values were used as criteria to select the best binding conformation among 10 generated by the program.
Results
Screen for inhibitors of Hfq-sRNA activity
To To identify inhibitors, E. coli pRybB pompC'-yfp was transformed with a library of plasmids encoding randomized cyclic peptides. The encoded cyclic peptides are produced using SICLOPPS technology, and have the sequence SGWX 5 . This library has been used to identify inhibitors of protein-protein interactions and enzymatic reactions (33) (34) (35) . Production of cyclic peptides, RybB, and OmpC'-YFP was induced and 2 X 10 6 cells were sorted using Fluorescence Activated Cell Sorting (FACS) (Fig. 1B) . The fluorescence histogram showed that the average cell fluorescence was ~2-fold higher in the population expressing a cyclic peptide, suggesting that the SICLOPPS system has a small effect on fluorescence. To identify potent inhibitors, the brightest 0.01% cells were collected and propagated as clonal populations. After growing each strain under inducing conditions, cells were examined using fluorescence microscopy. Most strains had increased levels of fluorescence, but one strain, expressing the cyclic peptide RI20, produced cells with fluorescence comparable to the E. coli pompC'-yfp positive control ( Fig. 2A) . The plasmid was isolated and retransformed into E. coli pRybB pompC'-yfp to verify that inhibition was due to the RI20 cyclic peptide. This strain was selected for further characterization. Sequencing of the plasmid encoding RI20 revealed that the on November 12, 2017 by guest http://aac.asm.org/ cyclic peptide sequence was SGWKVMEG.
RI20 inhibits Hfq-mediated repression
To quantify the efficiency of derepression by RI20, the fluorescence intensity of E.
coli pRybB pompC'-yfp cells was measured with and without RI20. Because cells without RI20 serve as the negative control, a cutoff for "dark cells" that have full repression of ompC'-yfp expression was set at the average intensity plus two standard deviations from cells without RI20. Using this measure, 98% of cells producing RI20 had de-repressed expression of ompC'-yfp ( Fig. 2A) .
Hfq-RybB promotes degradation of ompC mRNA, so inhibition of Hfq-RybB should increase the steady-state amount of ompC mRNA if synthesis rates are unchanged. With ompC'-yfp expressed from the P tet promoter, production of RI20 increased the steadystate level of ompC'-yfp mRNA 2-3-fold (Fig.2B ). This result is consistent with RI20
inhibiting Hfq-RybB-mediated degradation of ompC'-yfp mRNA.
The results described above show that RI20 inhibits Hfq-RybB repression at the ompC mRNA regulatory sequence in vivo. To determine if RI20 also inhibits Hfq-RybB activity on other mRNA sequences, the ompC sequence of the ompC'-yfp fusion was replaced with the cognate RybB recognition sequence from ompF ( Fig.3A) (30, 31, 36) and the fluorescence microscopy experiment was repeated with pompF'-yfp. When RI20
was produced, 96% of cells had de-repressed expression of ompF'-yfp (Fig. 3A) . These results indicate that RI20 is not specific for the RybB binding sequence in the ompC mRNA, and can inhibit Hfq-RybB activity on multiple mRNA targets. (Fig. 3B) (31, 37) . In cells producing MicF, production of RI20 de-repressed expression of ompF'-yfp in 40% of cells (Fig. 3B) . Therefore, RI20 also inhibited HfqMicF activity in vivo, but not as efficiently at Hfq-RybB.
Exogenous addition of RI20 inhibits Hfq-RybB
Most cyclic peptides produced using SICLOPPS in the SGWX 5 library have no effect on Hfq-RybB activity, indicating that expression of the split intein protein and the intein products of the circularization reaction are not responsible for the inhibition (Fig.1B) .
However, the reaction goes through a lariat intermediate that includes the randomized sequence and could, in principle, be responsible for the observed RI20 activity. To ensure that the in vivo activity of RI20 was due to the cyclic peptide, RI20 was chemically synthesized, purified, and added to cultures of E. coli pRybB pompC'-yfp at a final concentration of 500 M prior to analysis by fluorescence microscopy. 100% of the observed cells were de-repressed, demonstrating that the cyclic peptide form of RI20 is sufficient for inhibition of Hfq-RybB in vivo (Fig. 2C ).
RI20 inhibits Hfq binding to sRNAs in vitro
Because RI20 inhibits RybB repression of multiple mRNAs and also inhibits MicF, it is likely that RI20 acts at a shared step of the repression mechanism. One candidate step is binding of Hfq to the sRNAs. Gel mobility shift assays were used to measure the affinity of Hfq for RybB and MicF, and to test if RI20 inhibited binding. In the absence of peptide, the K d for binding of Hfq and RybB was ~90 nM, similar to previous reports (38) (Fig. 4A ). RI20 inhibited binding with an apparent K I = 111 μM (Figs. 4B-D Hfq binding of these sRNAs in a similar manner.
Sequence specificity for RI20 activity
To identify the residues required for RI20 activity in vivo, alanine scanning mutagenesis was performed on the KVMEG sequence. Each variant was produced using
SICLOPPS in E. coli pRybB pompC'-yfp and the expression of peptides in vivo was
confirmed by western analysis (data not shown). Quantification of fluorescence intensity revealed that substitution of alanine for the glutamate residue dramatically decreased RI20 inhibition and resulted in a fluorescence profile similar to that observed with no cyclic peptide present (Fig. 6) . A smaller decrease in inhibition was observed when alanine was substituted for the methionine residue. Substitution of the remaining amino acids with alanine had little effect on RI20 inhibition. Because western blotting showed that all mutant peptides were expressed at levels within 11% of RI20, differences in inhibition activity are unlikely to be caused by decreased expression. These results indicate that the glutamate is critical for RI20 activity in vivo, and the methionine also contributes to inhibition.
RI20 causes defects in oxidative stress survival and antibiotic resistance.
on November 12, 2017 by guest http://aac.asm.org/ Downloaded from E. coli strains deleted for hfq are more sensitive to oxidative stress and some antibiotics than wild-type cells (13, 40) . To determine if RI20 production also produces these defects, strains were challenged with hydrogen peroxide in a disk diffusion assay.
Wild-type cells producing RI20 and hfq cells both had a zone of inhibition >25%
greater than wild-type cells with no RI20 plasmid, indicating a greater sensitivity to oxidative stress (Table 3) . Likewise, wild-type cells producing RI20 and hfq cells were more sensitive to benzlkonium chloride and novobiocin than wild-type cells (Table 3 ).
These data indicate that RI20 expression phenocopies deletion of hfq.
Modeling of RI20 Hfq binding
To gain preliminary insights into the molecular mechanism of inhibition by RI20, modeling was used to predict potential binding sites for the cyclic peptide on Hfq. RI20 was docked onto the E. coli crystallographic model of the Hfq hexamer (PDB ID: 1HK9) using the AutoDock Vina program for modeling receptor/ligand interactions. RI20 is predicted to bind with an energy of -8.2 kcal/mol to the proximal face of Hfq, the surface responsible for interacting with sRNAs (Fig. 7A ). In the predicted structure, RI20 establishes four main contact points through hydrogen bonds with three Hfq monomers (Fig. 7B) . The glutamate required for RI20 function forms two hydrogen bonds with H57 of one Hfq monomer, one between the hydroxyl group of the E RI20 side chain and the backbone carbonyl group of H57 Hfq , and a second between the backbone carbonyl of E RI20 and the N of H57 Hfq , which is bridged by a solvent molecule (Fig. 7B) . A second 
Validation of Hfq-sRNA inhibitor screen under HTS conditions
Screening for high YPF fluorescence in the E. coli pRybB pompC'-yfp reporter strain successfully identified inhibitors of Hfq-sRNA activity using a FACS-based screen with a library of compounds expressed in vivo. To determine if the reporter could be used to screen compound libraries in high-throughput format, YFP fluorescence from E. coli pRybB pompC'-yfp and E. coli pompC'-yfp was measured in 96-well microtiter plates.
The average fluorescence in E. coli pompC'-yfp, the positive control strain mimicking full inhibition of Hfq-RybB activity, was 4-fold higher than that in E. coli pRybB pompC'-yfp, with Z' = 0.64 ± 0.04. These data indicate that the assay should be appropriate for high-throughput screening.
Discussion
The work presented here demonstrates that regulation of gene expression by HfqsRNAs can be inhibited using drug-like compounds such as cyclic peptides, and that the assay system described here can identify inhibitors. Using a cell-based assay with positive readout, RI20 was identified from a library of cyclic peptides expressed inside the E. coli cell. Although the assays used the RybB sRNA, RI20 has the expected properties of an inhibitor that blocks Hfq interaction with multiple sRNAs. In vivo, it inhibited RybB-dependent repression of two mRNA targets and repression by a second The mechanism by which Hfq binds a diverse set of cellular sRNAs is still under investigation. Current evidence suggests that Hfq has two different binding modes for sRNAs. A site on the proximal face of the Hfq hexamer binds 3' U-rich regions, similar to those found in rho-independent transcription terminator sequences shared by many sRNAs (28, (41) (42) (43) . Sites along the lateral sides of the hexamer are thought to bind to the body of the sRNAs (44) . Given the similar K I values for RybB and MicF, it is likely that RI20 prevents binding of these sRNAs to Hfq in a similar manner. RybB and MicF share little sequence similarity outside of the transcriptional terminator region that binds the proximal face of Hfq, so this interaction is a strong candidate for the site of RI20 activity.
Consistent with this prediction, the energy-minimized docking of RI20 to the Hfq hexamer suggests that there is a possible binding site for RI20 on the proximal face (Fig.7) . Future experimental studies are warranted to confirm these predictions.
RI20 itself is not a candidate anti-infective because the K I is too high and high concentrations are needed to inhibit Hfq when the peptide is added to cells exogenously.
Nevertheless, it has some properties that would be advantageous in an anti-infective.
on November 12, 2017 by guest http://aac.asm.org/ RI20 inhibits two sRNAs, and because the proximal face of Hfq is thought to bind all Hfq-dependent sRNAs, RI20 is likely to inhibit all Hfq-sRNA interactions. This broad specificity would prevent cells from circumventing drug activity by expressing an sRNA with redundant function, and would allow a drug to be used on species that employ Hfq for virulence factor production without knowledge of the particular sRNA that is important. The predicted interaction with H57 Hfq would also limit the acquisition of resistance through mutations in Hfq, because H57 Hfq is required for Hfq oligomerization as well as sRNA binding (45), although mutations to other residues could potentially decrease RI20 binding and lead to resistance. A small molecule that binds to the same site as RI20 would be a candidate anti-infective. Such compounds could be rationally designed once the structure of RI20 bound to Hfq is known, or they could be identified by HTS using the assay described here.
The assay system used in this study is a cell-based assay with positive readout, which is readily adaptable to high-throughput formats and provides several advantages for high-throughput screening. Compounds added externally would have to pass through the cell membrane to inhibit Hfq-sRNA activity, minimizing hits with low permeability.
The overall screening strategy is particularly powerful because the assay relies on a positive read-out, gain of fluorescence, rather than loss of signal. Therefore, false positive hits due to molecules that interfere with production of the reporter gene or cell growth will not be recovered. This assay is also easily adaptable for identification of inhibitors of other sRNAs by replacing the RybB and OmpC' sequences with cognate sRNA and target sequences, respectively. Future identification of small molecule inhibitors of Hfq will allow validation of Hfq as a therapeutic target in vivo. 
Tables
